



# Balfour Capital Group Danaher Corporation

Danaher Corporation is a global science and technology innovator specializing in life sciences, diagnostics, and biotechnology. Founded in 1984 by Steven and Mitchell Rales, the company is headquartered in Washington, D.C. Danaher operates through a portfolio of businesses that develop and manufacture professional, medical, industrial, and commercial products and services. The company is known for implementing the Danaher Business System (DBS), a continuous improvement methodology inspired by lean manufacturing principles.

## 1. Top 5 Competitors

Danaher's primary competitors in the life sciences and diagnostics sectors include:

1. Thermo Fisher Scientific
2. Agilent Technologies
3. Abbott Laboratories
4. Siemens Healthineers
5. Roche

These companies compete with Danaher across various segments, including analytical instruments, diagnostics, and life sciences tools.

## 2. Largest Institutional Shareholders

As of the latest filings, the largest institutional shareholders of Danaher are:

- The Vanguard Group, Inc. – 8.38% ownership
- BlackRock, Inc. – 7.35% ownership
- State Street Global Advisors, Inc. – 3.83% ownership
- T. Rowe Price Group, Inc. – 3.74% ownership
- Capital Research and Management Company – 2.91% ownership

## 3. Management Team

- Rainer M. Blair – President and Chief Executive Officer
- Matthew R. McGrew – Executive Vice President and Chief Financial Officer
- Julie Sawyer Montgomery – Executive Vice President, Diagnostics Platform
- Steven Rales – Co-Founder and Chairman

Mitchell Rales – Co-Founder and Director



# Balfour Capital Group Danaher Corporation

## 4. Revenue

For the twelve months ending March 31, 2025, Danaher reported revenues of approximately \$23.82 billion, reflecting a slight year-over-year decrease of 0.35%.

## 5. Institutions with Buy Recommendations:

Several financial institutions have issued buy ratings for Danaher, including:

- Goldman Sachs – Upgraded to Buy with a price target of \$260
- Barclays – Upgraded to Overweight with a price target of \$205
- RBC Capital Markets – Maintained Outperform rating with a price target of \$250
- Evercore ISI – Maintained Outperform rating with a price target of \$240
- Guggenheim – Maintained Buy rating with a price target of \$250

## 6. Analyst Sentiment Summary

Analyst sentiment towards Danaher is predominantly positive:

- Buy Ratings: 24
- Hold Ratings: 3
- Sell Ratings: 0
- Average Target Price: \$247.05
- Price Target Range: \$210.00 to \$310.00

This reflects a potential upside of approximately 26% from current levels.

## 7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, Danaher insiders have sold a total of 1,560,673 shares, amounting to approximately \$324.26 million. MarketBeat

Notably, in the past 90 days, there have been significant insider sales totaling around \$249 million, with Chairman Steven M. Rales accounting for over \$200 million of these transactions.